Gilead Sciences (GILD) was Reiterated by RBC Capital Mkts to “Outperform” while Lowering the Price Target of the company shares to $ 95 from a previous price target of $105 . RBC Capital Mkts advised their investors in a research report released on Oct 3, 2016.
Many Wall Street Analysts have commented on Gilead Sciences. Shares were Reiterated by RBC Capital Mkts on Oct 3, 2016 to “Outperform” and Lowered the Price Target to $ 95 from a previous price target of $105 .Shares were Downgraded by Leerink Partners on Sep 27, 2016 to ” Mkt Perform” and Lowered the Price Target to $ 94 from a previous price target of $112 .Berenberg Initiated Gilead Sciences on Sep 12, 2016 to “Buy”, Price Target of the shares are set at $112.
On the company’s financial health, Gilead Sciences reported $3.08 EPS for the quarter, beating the analyst consensus estimate by $ 0.07 according to the earnings call on Jul 25, 2016. Analyst had a consensus of $3.01. The company had revenue of $7776.00 million for the quarter, compared to analysts expectations of $7795.08 million. The company’s revenue was down -5.7 % compared to the same quarter last year.During the same quarter in the previous year, the company posted $3.15 EPS.
Gilead Sciences opened for trading at $78.06 and hit $79.63 on the upside on Friday, eventually ending the session at $79.12, with a gain of 1.62% or 1.26 points. The heightened volatility saw the trading volume jump to 1,10,31,540 shares. Company has a market cap of $104,411 M.
In a different news, on Sep 26, 2016, Gregg H Alton (EVP Comm&Acs ALA, Corp&Med Aff) sold 5,000 shares at $81.84 per share price. According to the SEC, on Sep 8, 2016, John F Milligan (President and CEO) sold 70,000 shares at $77.74 per share price. On Sep 6, 2016, John C Martin (Executive Chairman) sold 100,000 shares at $77.82 per share price, according to the Form-4 filing with the securities and exchange commission.
Gilead Sciences Inc. (Gilead) is a research-based biopharmaceutical company that discovers develops and commercializes innovative medicines. The Companys primary areas of focus include human immunodeficiency virus (HIV) liver diseases such as chronic hepatitis C virus (HCV) infection and chronic hepatitis B virus (HBV) infection oncology and inflammation and serious cardiovascular and respiratory conditions. The Companys HIV products include Stribild Complera/Eviplera Atripla Truvada Viread Emtriva Tybost and Vitekta. Its Liver Diseases products include Harvoni Sovaldi Viread and Hepsera. Zydelig is the Companys oncology product. Its Cardiovascular products include Letairis Ranexa and Lexiscan/Rapiscan. Its Respiratory products include Cayston and Tamiflu. Its other products include AmBisome and Macugen.